November 4, 2021 -- Bluebird Bio spinoff 2seventy bio has officially launched as an independent, publicly traded company and will trade on the Nasdaq Global Select Market starting November 5 under the ticker symbol TSVT.
2seventy's pipeline includes a range of candidates for use in treating hematologic and solid tumors, including two therapies that are projected to enter trials in the first half of 2022. The company's portfolio also includes a development and commercialization partnership in the U.S. with Bristol Myers Squibb (BMS) for Abecma, a B-cell maturation, antigen-directed, CAR T-cell immunotherapy for multiple myeloma.
Abecma generated $67 million in U.S. sales in the third quarter of 2021, its first full quarter after launch, 2seventy said. BMS and 2seventy are pursuing additional clinical studies in earlier lines of treatment for patients with multiple myeloma, the company said.